Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone oral - Soligenix

Drug Profile

Beclometasone oral - Soligenix

Alternative Names: BDP; DOR 201; DOR 202; DOR 203; Oral BDP - Soligenix/Sigma-Tau; Oral beclomethasone 17,21-dipropionate; orBec; OrbeShield; SGX 201; SGX 202; SGX 203

Latest Information Update: 01 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enteron Pharmaceuticals
  • Developer Fred Hutchinson Cancer Research Center; National Institutes of Health (USA); Soligenix
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Crohn's disease; Acute radiation syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Crohn's disease; Radiation injuries
  • Phase I Acute radiation syndrome
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 29 Jul 2019 Soligenix has patent protection for beclometasone oral in European Union
  • 24 Jun 2018 Biomarkers information updated
  • 04 Dec 2017 Beclometasone oral is still in phase I/II trials for Crohn's disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top